METHOTREXAT EBEWE 2.5 MG (METHOTREXATE)

50 Tablets | Oral Antimetabolite and Immunosuppressant

Medical Description

Methotrexat Ebewe 2.5 mg contains methotrexate, a folate antagonist belonging to the antimetabolite class of medications. It possesses immunosuppressive, anti-inflammatory, and antineoplastic properties, making it useful in the management of various autoimmune, inflammatory, and malignant conditions.

Methotrexate works by interfering with folate metabolism and inhibiting cellular DNA synthesis. At low doses, it also produces immunomodulatory and anti-inflammatory effects that help control excessive immune system activity.

It is commonly prescribed for inflammatory conditions such as rheumatoid arthritis, severe psoriasis, and psoriatic arthritis. It may also be used in selected cancer treatment protocols under specialist supervision.

Methotrexat Ebewe 2.5 mg provides a low-strength oral formulation that allows individualized dosing according to the patient's condition, therapeutic response, and tolerability.

For inflammatory conditions such as rheumatoid arthritis and psoriasis, methotrexate is generally administered ONCE WEEKLY, NOT DAILY. Accidental daily administration can cause severe toxicity, including potentially fatal bone marrow suppression and organ damage.

Active Ingredient

• Active ingredient: Methotrexate.
• Pharmacological class: Antimetabolite and folic acid antagonist.
• Dosage form: Oral tablets.
• Pack size: 50 tablets.

Methotrexate interferes with folate-dependent biochemical pathways involved in DNA synthesis and cellular proliferation.

Indications and Uses

Methotrexat Ebewe may be prescribed for:

1. Rheumatoid Arthritis: Helps reduce joint inflammation, swelling, pain, and disease activity in adults with active rheumatoid arthritis.
2. Severe Psoriasis: Helps control excessive skin cell proliferation and inflammatory skin lesions in patients who have not responded adequately to conventional treatments.
3. Psoriatic Arthritis: Helps manage inflammatory joint symptoms and disease activity.
4. Juvenile Idiopathic Arthritis: Used in selected children, including patients with polyarticular disease, under specialist supervision.
5. Certain Malignancies: Methotrexate is also used in specific oncology protocols for certain cancers, including acute lymphoblastic leukaemia and selected lymphomas.

The approved indications may vary according to the national product registration and treatment protocol.

Mechanism of Action

Methotrexate exerts its therapeutic effects through several complementary mechanisms:

• Folate Antagonism: Inhibits dihydrofolate reductase (DHFR), an enzyme required for the conversion of folate into its active form.
• Inhibition of DNA Synthesis: Reduces the availability of folate-dependent compounds required for DNA and RNA synthesis, limiting cellular proliferation.
• Anti-inflammatory Activity: At low doses, increases extracellular adenosine activity, helping reduce inflammatory responses.
• Immunomodulatory Effects: Modifies the activity of immune cells and inflammatory pathways, helping control autoimmune disease activity.
• Antineoplastic Activity: At higher doses, interferes with the growth and multiplication of rapidly dividing malignant cells.

Dosage and Administration

The dosage depends on the indication, disease severity, body weight, kidney and liver function, and clinical response.

Common adult dosage references for inflammatory conditions:

• For inflammatory and autoimmune conditions, methotrexate is generally administered as a single weekly dose on the same day each week.
• The 2.5 mg tablets allow the physician to calculate the required weekly dose.
• Swallow the tablets with water according to the prescribed instructions.
• Folic acid supplementation is commonly prescribed to reduce certain adverse effects.
• Oncology treatment requires different dosing schedules and specialist-directed protocols.

Important: Methotrexate dosing errors can cause severe and potentially fatal toxicity. Patients should receive clear written instructions specifying the exact number of tablets and the designated day of administration.

Contraindications

Methotrexate Ebewe is contraindicated or generally unsuitable in patients with:

• Pregnancy when prescribed for non-malignant conditions.
• Breastfeeding.
• Known hypersensitivity to methotrexate or any product ingredient.
• Severe liver disease or significant hepatic impairment.
• Severe renal impairment.
• Significant pre-existing blood disorders or bone marrow suppression.
• Severe active infections or serious immunodeficiency.
• Excessive alcohol consumption or alcohol-related liver disease, depending on the clinical assessment.

Possible Side Effects

Common adverse effects:

• Nausea and vomiting.
• Abdominal discomfort.
• Diarrhoea.
• Loss of appetite.
• Mouth ulcers and stomatitis.
• Fatigue and weakness.
• Hair thinning or hair loss.
• Elevated liver enzymes.
• Increased susceptibility to infections.

Serious adverse effects:

• Bone Marrow Suppression: Reduced production of blood cells, potentially causing anaemia, leukopenia, neutropenia, and thrombocytopenia.
• Hepatotoxicity: Liver inflammation, elevated liver enzymes, and potentially chronic liver injury.
• Pulmonary Toxicity: Methotrexate-associated pneumonitis, which may present with persistent cough, fever, and difficulty breathing.
• Renal Toxicity: Kidney injury, particularly in patients with impaired renal function.
• Severe Gastrointestinal Toxicity: Significant mucositis, ulceration, and gastrointestinal bleeding.
• Severe Skin Reactions: Rare but potentially life-threatening dermatological reactions.
• Serious Infections: Increased susceptibility to bacterial, viral, and opportunistic infections.

Precautions and Warnings

• Weekly Dosing: For inflammatory diseases, methotrexate must be taken once weekly, never daily. Patients should maintain a written dosing schedule.
• Blood Monitoring: Regular complete blood counts (CBC) are essential to detect bone marrow suppression.
• Liver Function: Periodic liver function tests are required because methotrexate may cause hepatotoxicity.
• Kidney Function: Renal function should be assessed before and during treatment, as impaired clearance may increase methotrexate toxicity.
• Pregnancy: Methotrexate can cause fetal abnormalities and pregnancy loss. Effective contraception and appropriate post-treatment precautions are necessary.
• Drug Interactions: Certain antibiotics, particularly trimethoprim/sulfamethoxazole, NSAIDs, and other medications affecting renal clearance or bone marrow function, may increase toxicity.
• Folic Acid: Supplementation is commonly recommended during low-dose treatment according to the physician's instructions.
• Alcohol: Alcohol consumption should generally be avoided because of the increased risk of liver toxicity.
• Infections: Patients should promptly report fever, persistent infections, or unusual symptoms.
• Pulmonary Symptoms: New or persistent cough, fever, or breathing difficulties require immediate medical evaluation.
• Vaccination: Live vaccines are generally avoided during immunosuppressive methotrexate treatment.

Storage Conditions

• Store below 25°C, according to the product information.
• Keep in the original packaging to protect from light.
• Protect from excessive moisture.
• Keep out of reach of children.
• Handle and dispose of tablets according to appropriate precautions for cytotoxic medications.

Patient Disclaimer

Methotrexat Ebewe is a prescription-only medication that must be used strictly under medical supervision. This information is provided for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

For inflammatory conditions, methotrexate is generally taken ONCE WEEKLY, NOT DAILY. Incorrect administration can cause severe or potentially fatal toxicity. Regular blood counts, liver function, and kidney function monitoring are essential during treatment. Methotrexate can cause serious fetal harm and must not be used during pregnancy for non-cancerous conditions. Never adjust or discontinue treatment without consulting your healthcare provider.

References

1. Methotrexat Ebewe – Summary of Product Characteristics: Product-specific composition, indications, dosage, contraindications, and safety information. Methotrexat Ebewe 2.5 mg – SmPC.
2. Methotrexat Ebewe – Updated Product Information: Important weekly-dosing warning and medication safety requirements. Ebewe – Updated Safety Information.
3. U.S. National Library of Medicine (NIH – DailyMed): Methotrexate prescribing information, pharmacology, adverse effects, and boxed warnings. DailyMed – Methotrexate Tablets.
4. National Health Service (NHS): Methotrexate administration, weekly dosing, folic acid supplementation, and overdose precautions. NHS – How and When to Take Methotrexate.
5. National Health Service (NHS): Clinical uses, pharmacological effects, and treatment precautions. NHS – About Methotrexate.
6. Electronic Medicines Compendium (eMC): Methotrexate 2.5 mg Summary of Product Characteristics. Methotrexate – eMC Clinical Information.